Details of the Drug Combinations

General Information of This Drug (ID: DMVYRH2)

Drug Name

Perifosine DMVYRH2

Synonyms

D 21266; NKA17; D-21266; KRX-0401; KRX-0401, NSC 639966; Octadecyl-(1,1-dimethyl-4-piperidylio)phosphate; Piperidinium, 4-[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt; Piperidinium, 4-((hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethyl-, inner salt; (1,1-dimethylpiperidin-1-ium-4-yl) octadecyl phosphate; 4-((Hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethylpiperidinium inner salt

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Perifosine + Mitomycin	DCSVPBG	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
Perifosine + Ibrutinib	DCK5F42	Ibrutinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
------------------------------------------------------------------------------------

7 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Bortezomib + Perifosine	DCJ3MVB	Bortezomib	Multiple Myeloma	[3]
Capecitabine + Perifosine	DCGI2GR	Capecitabine	Colon Cancer	[4]
Dexamethasone + Perifosine	DCIM353	Dexamethasone	Multiple Myeloma	[5]
Docetaxel + Perifosine	DC7OT9R	Docetaxel	Ovarian Cancer	[6]
Docetaxel + Perifosine	DCOCHZX	Docetaxel	Neoplasms	[7]
Temsirolimus + Perifosine	DCAF92R	Temsirolimus	Brain Tumor, Recurrent	[8]
UCN-01 + Perifosine	DCR4NGT	UCN-01	Accelerated Phase Chronic Myelogenous Leukemia	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DrugCom(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7424).
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	ClinicalTrials.gov (NCT00401011) Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
4	ClinicalTrials.gov (NCT00398879) Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
5	ClinicalTrials.gov (NCT00375791) Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
6	ClinicalTrials.gov (NCT00431054) Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
7	ClinicalTrials.gov (NCT00399087) Phase I Trial of Docetaxel With Perifosine
8	ClinicalTrials.gov (NCT02238496) Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
9	ClinicalTrials.gov (NCT00301938) 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes